-2%
Rsudil Plus is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Use in elderly patients: No overall differences in safety and effectiveness have been observed between elderly and other adult patients.
Rsudil Plus is a fixed-dose combination of a Rho kinase inhibitor and a Prostaglandin F2 analogue. Netarsudil is a Rho kinase inhibitor that works at the cellular level within the trabecular outflow pathway to relax actin-myosin. This causes relaxation within the trabecular meshwork and the inner wall of Schlemm’s canal, and decreases episcleral venous pressure (EVP).
Latanoprost is a selective FP receptor agonist that reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humor through uveoscleral outflow.
The recommended dosage is one drop in the affected eye(s) once daily in the evening.
Rsudil Plus drops are contraindicated in patients who are hypersensitive to any component of this preparation.
The most common ocular adverse reaction observed in controlled clinical studies with Netarsudil & Latanoprost was conjunctival hyperemia, instillation site pain, corneal verticillata, instillation site discomfort, foreign body sensation, and blurred vision were reported in a few patients.
There are no adequate and well-controlled studies of Netarsudil & Latanoprost combination in pregnant women to inform any drug-associated risk. There are no data on the presence of Netarsudil or Latanoprost in human milk, the effects on the breastfed infant, or the effects on milk production.